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ABSTRACT
Systematic review of published population based surveys
to examine the relationship between primary open angle
glaucoma (POAG) prevalence and demographic factors.
A literature search identiﬁed population-based studies
with quantitative estimates of POAG prevalence (to
October 2014). Multilevel binomial logistic regression of
log-odds of POAG was used to examine the effect of
age and gender among populations of different
geographical and ethnic origins, adjusting for study
design factors. Eighty-one studies were included (37
countries, 216 214 participants, 5266 POAG cases).
Black populations showed highest POAG prevalence,
with 5.2% (95% credible interval (CrI) 3.7%, 7.2%)
at 60 years, rising to 12.2% (95% CrI 8.9% to 16.6%)
at 80 years. Increase in POAG prevalence per decade of
age was greatest among Hispanics (2.31, 95% CrI 2.12,
2.52) and White populations (1.99, 95% CrI 1.86,
2.12), and lowest in East and South Asians (1.48, 95%
CrI 1.39, 1.57; 1.56, 95% CrI 1.31, 1.88, respectively).
Men were more likely to have POAG than women (1.30,
95% CrI 1.22, 1.41). Older studies had lower POAG
prevalence, which was related to the inclusion of
intraocular pressure in the glaucoma deﬁnition. Studies
with visual ﬁeld data on all participants had a higher
POAG prevalence than those with visual ﬁeld data on a
subset. Globally 57.5 million people (95% CI 46.4 to
73.1 million) were affected by POAG in 2015, rising to
65.5 million (95% CrI 52.8, 83.2 million) by 2020.
This systematic review provides the most precise
estimates of POAG prevalence and shows omitting
routine visual ﬁeld assessment in population surveys may
have affected case ascertainment. Our ﬁndings will be
useful to future studies and healthcare planning.
INTRODUCTION
Glaucoma is a major public health problem, being
the leading cause of irreversible visual impairment
worldwide.1 Primary open angle glaucoma (POAG)
is the most common type of glaucoma accounting
for three-quarters (74%) of all glaucoma cases.2
A recent review estimated the global number of
POAG cases in 2013 at 44 million, rising to 53
million by 2020 due to population ageing.3
However, uncertainty about the number of people
with POAG still remains, as these global estimates
are associated with a twofold difference in CIs
(ie, estimates ranged from 31 million to 61 million
cases in 2013, increasing to 37 million to 73
million in 2020).3 Such uncertainty makes it difﬁ-
cult to accurately plan appropriate health services.
Reasons for this uncertainty are numerous and
relate to geographical variations in underlying
POAG prevalence, as well geographical representa-
tion of surveys to ascertain prevalence, and differ-
ences in study methods of case ascertainment.
Previous population-based surveys have been
carried out largely in White populations.4 5
A meta-analysis carried out by our group nearly a
decade ago showed higher prevalence in Black
populations compared with White populations and
Asians, but there were little data on other ethnic
groups, such as South and East Asians or Hispanics,
at that time.5 Since then, many large population
based studies have been carried out to examine
prevalence of POAG in different ethnic groups and
geographical locations.3 A recent review showed
that the greatest increase of POAG cases is esti-
mated to be in lower income countries, particularly
Asia, due to more rapid ageing compared with
countries of European ancestry. This will have con-
siderable impact on the total number of cases, as
Asia has 60% of the world’s adult and aged popula-
tion. However, these estimates did not examine
geographical variation in POAG prevalence within
Asia, which may be important as any potential
error in estimation is magniﬁed when applied to
large population numbers.
Moreover, different methods of ascertaining
POAG cases will artefactually alter estimates of
population prevalence.5 Standardisation of POAG
deﬁnitions by the International Society for
Geographical and Epidemiological Ophthalmology
(ISGEO) has sought to establish a survey-speciﬁc
distribution of optic disc parameters to deﬁne ‘nor-
mality’, allowing studies in less developed countries
to contribute to the world literature on glaucoma
prevalence.6 These deﬁnitions avoid historic over-
reliance on elevated intraocular pressure (IOP)
being a necessary prerequisite for glaucoma diagno-
sis, and place greater emphasis on visually signiﬁ-
cant ‘end organ damage’. However, the potential
effect of these deﬁnitions on case ascertainment is
unknown, and has not been formally investigated.
For these reasons, we have updated our review
to include data from a larger number of studies. We
have adopted a more inclusive approach than
another recent review,3 to increase the number of
cases and participants, in order to establish with
greater precision the strength of the relation
between POAG prevalence, ethnicity, age and
gender. The increase in numbers also allows trends
in POAG prevalence through time and the effect of
study design on prevalence to be examined with
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greater certainty, allowing more accurate estimation of the
global/regional prevalence and case burden of POAG currently
and over the next decade.
METHODS
Systematic search strategy
The systematic review was carried out by three investigators
(MPYC, ARR and VVK) and followed the Meta-analysis of
Observational Studies in Epidemiology guidelines for the
reporting of systematic review and meta-analysis of observa-
tional studies.7 The search reviewed all published papers, letters,
abstract and review articles published on MEDLINE, EMBASE
and Web of Science electronic databases from January 2005 to
October 2014. Papers published before 2005 were identiﬁed
from our earlier review.5 A combination of text words for glau-
coma (glaucoma/open angle glaucoma/primary open angle glau-
coma/primary glaucoma) and epidemiological terms (incident
$/prevalen$/population$/survey$) were used, in addition to
related subject headings in MEDLINE, EMBASE and Web of
Science.
Inclusion and exclusion criteria
Studies were included if they provided quantitative estimates of
POAG prevalence in population-based surveys, where the geo-
graphical, random or clustered population sampling method was
clearly deﬁned. Studies were only included if optic disc assess-
ment was carried on all participants (ie, not a subset or random
sample). Studies reporting audits of hospital eye departments or
clinics, or inviting non-speciﬁc volunteers were excluded.
Studies were not excluded on the basis of clinical deﬁnitions of
POAG or methods used to diagnose POAG cases; studies using
self-reported diagnosis of glaucoma were excluded. Attempts
were made to contact authors for further clariﬁcation of details
where necessary.
Studies identiﬁed and data extraction
In total, 5434 studies were identiﬁed and underwent abstract
review; 5282 studies were excluded based on the criteria
deﬁned above. The QUOROM statement in online supplemen-
tary ﬁgure S1 shows the article selection process. A list of
excluded papers is available from the authors; 81 studies that
reported the prevalence of POAG from a deﬁned population-
based survey were included in the analysis (including 46 studies
identiﬁed previously from our earlier review).5 Data from these
studies were extracted by three reviewers (MPYC, VVK and
ARR), with independent extraction in a subset. Disagreements
in data extraction were resolved by discussion.
Data were extracted on a number of key indicators of study
quality, identiﬁed a priori. These included method of POAG
diagnosis (whether the deﬁnition was based on visual ﬁeld (VF)
results; whether IOP was included in the case deﬁnition), and
whether these assessments were carried out in all or a subset of
participants, in one or both eyes. Where possible, POAG preva-
lence excluding cases of pseudoexfoliation syndrome was
sought. In studies published after 2000, we also recorded
whether the study conformed to ISGEO criteria for POAG diag-
nosis,6 and if so, whether VF assessment was carried out on all
participants, a subset of high-risk or a proportion of random
participants. Data were also extracted on study response rates,
habitation type (urban, rural or mixed) and year of survey (mid-
point when a study period was reported). Missing data on
survey year were imputed for 13 studies by subtracting 4 years
from the year that the article was published (based on the
median time to publication, in studies with available data). Data
were extracted by gender and ethnic/racial group where avail-
able. Ethnicity was classiﬁed into the groups listed below,
broadly following deﬁnitions of the United Nations (UN) and
WHO:
A. White European ancestry (ie, European, Brazilian,
American, Australian, New Zealander)
B. East Asian (ie, Chinese, Japanese, Mongolian, South
Korean)
C. South Asian (ie, Indian, Sri Lankan and Bangladeshi)
D. South-East Asian (ie, Singaporean, Myanmarese and Thai)
E. Black African Caribbean ancestry (ie, Ghanaian, African
American, Black Caribbean, Black British)
F. Hispanic or Latino (ie, Hispanic or Latino in USA)
G. Other or mixed (ie, Eskimo, mixed South African, indigen-
ous Australian, Qatari, Iranian, mixed non-white).
Statistical analysis
All statistical analyses were carried out using OpenBUGS
(V.3.2.2)8 and R (V.3.1.1).9 We used Bayesian multilevel
mixed-effects binomial logistic regression to investigate the asso-
ciations between the log odds of POAG in either eye and poten-
tial modifying factors, including age, gender, ethnicity, year of
survey and study design factors such as methods of diagnosis.
Our previous review5 demonstrated ethnic differences in the
prevalence of POAG with age. Therefore, the effect of age was
allowed to differ by ethnic group by including an interaction
term in the models. Year of survey was included in the models
as a categorical variable with four levels (ie, 1960–1979, 1980–
1989, 1990–1999, and 2000 or later). The effect of study
design was assessed in two ways: ﬁrst, by including dummy vari-
ables indicating whether VF testing was routinely performed on
all participants and whether an IOP criteria were used, allowing
for an interaction between the two variables; and second, for
surveys conducted since 2000 by including a variable indicating
whether a study followed ISGEO classiﬁcation of glaucoma (and
if so, whether VF assessment was carried out on all or a subset
of participants) or not. The effect of gender was estimated from
a separate model using the subset of studies that reported
gender-speciﬁc prevalence, adjusting for study design, age, eth-
nicity and an interaction between age and ethnicity. All analyses
included a random component for each study population, to
take into account the correlation of prevalence estimates within
the same study population. A study population was deﬁned as
the same ethnicity examined at the same time in the same geo-
graphical location.
Modelled age, gender and ethnic speciﬁc prevalence estimates
were standardised to studies that routinely used VFs on all parti-
cipants to diagnose POAG, and applied to UN demographic
data for 2015, 2020 and 2025.10 We selected the dominant
ethnic group for the following UN deﬁned regions (1) Black—
Africa and the Caribbean, (2) White—Europe, North America,
Western Asia, Australia and New Zealand, (3) Hispanic—
Central and Southern America, (4) Other/mixed—Melanesia,
Micronesia and Polynesia. More detailed ethnic division was
possible for Asia where (5) East Asian was used to represent
Eastern and Central Asia, (6) South Asian—Southern Asia, and
(7) South-East Asian—South-Eastern Asia. Mid age band preva-
lence estimates were applied to 5-year population data from 40
years to 90 years, to obtain population numbers with POAG,
overall and by region, with associated 95% credible intervals
(CrIs). In the population with age 90 years or more, prevalence
estimates at 92 years were applied. A full description of all statis-
tical models is available as online supplementary statistical
appendix.
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RESULTS
In total, 81 articles met the inclusion criteria. They examined
POAG prevalence in population based surveys published
between 1966 to 2014, involving 5266 cases of POAG among
216 214 individuals. Online supplementary table S1 provides
the key features of each individual article included in the review,
including the number of POAG cases, number of participants,
age range of participants, survey years, habitation type and
methods used to diagnose POAG cases. Table 1 summarises the
studies contributing to the overall and gender-speciﬁc analyses,
including the number of studies, POAG cases and participants
by ethnic group. Most studies were carried out in White popula-
tions (36%, 29/81), with fewer studies in South Asian and East
Asian (19.8%, 16/81; 18.5%, 15/81 respectively), Black (16%,
13/81), and a smaller number of studies in South-East Asian
(6%, 5/81), Hispanic or Latino (2.5%, 2/81) and mixed ethnic
populations (table 1). Table 2 examines the effect of important
population and study level covariates on the risk of POAG,
including age, ethnicity, year of survey and methods of POAG
diagnosis. The risk of POAG increased with age across all ethnic
groups. As in our previous review,5 we modelled ethnic-speciﬁc
associations with age. The risk of POAG per decade in age was
highest among Hispanics (2.3 times greater risk per decade in
adjusted analyses), followed by White populations with a doub-
ling of risk, South Asians (1.7 greater risk per decade), Black
populations and South-East Asians (1.6 greater risk per decade),
and lowest among East Asians (with approximately a 1.5 times
greater risk per decade) (table 2). Men showed 33% higher risk
of POAG (OR=1.33, 95% CrI 1.24, 1.42), with no evidence
that the effect of gender differed across ethnic groups. This
effect remained after adjustment for other study covariates,
including age and study design factors. Older studies had pro-
gressively lower risk of POAG, and historic studies (1960–1979)
report signiﬁcantly lower POAG prevalence than studies after
year 2000 (OR=0.45, 95% CrI 0.24, 0.89). However, given
shifts in diagnostic methods over time (ﬁgure 1), adjustment for
year of survey and study methods (including the extent of VF
testing and/or use of an IOP criterion), was not carried out due
to concerns over collinearity. In sensitivity analysis, there was no
evidence of an effect of calendar year on POAG risk after year
2000. In terms of study methods, there was no evidence that
ISGEO diagnosis modiﬁed POAG risk among studies published
over the period when guidelines were introduced (ie, post
2002).6 However, in all studies, including those published
before ISGEO guidelines, reliance on IOP in POAG diagnosis
reduced the POAG prevalence compared with studies routinely
performing VFs on all participants to diagnose POAG (table 2).
While this effect was attenuated with adjustment for other study
covariates, the effect was marginally stronger when studies
including IOP assessment in diagnosis were pooled (40 study
populations, unadjusted pooled OR 0.59, 95% CrI 0.41, 0.88;
adjusted pooled OR 0.78, 95% CrI 0.58, 1.01). Figure 1 shows
the proportion of studies performing VFs on all participants or
relying on IOP to obtain POAG diagnosis over time. A shift
away from relying on IOP to diagnose POAG is clearly shown.
While studies have increasingly undertaken VF testing on all
participants to diagnose POAG over time, fewer studies used
routine VF testing on all participants from 2005 onwards.
Ethnic speciﬁc prevalence of POAG by age is given in table 3.
Estimates are standardised to surveys that performed VF but not
IOP assessment on all participants. The corresponding estimates
for White men and White women, along with prevalence by
year of age with greater granularity are given in online supple-
mentary table S2. All ethnic groups showed a log-linear increase
in POAG prevalence with age but the slope of the log-linear
association differed by ethnic group (ﬁgure 2). While the age-
dependent increase in POAG prevalence is highest for White
populations and Hispanics, Black populations have the highest
absolute levels of POAG prevalence at each age, except above
age 80 years, where the prevalence is highest among Hispanics
(table 3, ﬁgure 2).
Although we observed weak evidence of a higher odds of
POAG in populations from urban compared with rural popula-
tions, once we adjusted for the ethnic-speciﬁc associations with
Table 1 Summary of the number of study populations with data on primary open angle glaucoma (POAG) prevalence by ethnic group
Ethnicity
Study
K N n
Survey years
Populations Range Mean*
Prevalence reported in men and women combined
White 29 107 60 465 1188 1963–2002 1987
Black 13 68 24 258 1363 1966–2009 1995
East Asian 15 38 56 400 1182 1985–2010 2002
South Asian 16 50 44 384 743 1990–2008 2002
South-East Asian 5 10 9302 254 1997–2005 2002
Hispanic or Latino 2 11 10 916 385 1998–2003 2001
Other/mixed 8 17 10 489 151 1969–2011 2002
Prevalence reported in men and women separately (subset of all studies)
White 20 148 40 012 706 1963–2002 1989
Black 6 36 15 249 1028 1986–2009 1997
East Asian 12 66 45 711 690 1988–2010 2002
South Asian 8 58 25 308 480 1998–2008 2003
South-East Asian 3 12 6604 187 1997–2005 2001
Hispanic or Latino 2 12 10 929 385 1998–2003 2001
Other/Mixed 3 18 3069 21 1969–1992 1985
K: Total number of available estimates of prevalence.
N: Total number of participants (published or estimated).
n: Total number of cases of POAG (published or estimated).
*Mean survey year weighted by study population size.
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Table 2 ORs of primary open angle glaucoma (POAG) for a decade increase in age, trends over time and study design factors
All surveys Surveys conducted since 2000
Factor
Study Unadjusted OR* Adjusted OR† Adjusted OR†
populations (95% CrI) (95% CrI) (95% CrI)
Effect per decade increase in age by racial group
White 29 1.99 (1.86, 2.13) 1.99 (1.86, 2.12) 1.97 (1.50, 2.64)
Black 13 1.60 (1.52, 1.67) 1.59 (1.52, 1.67) 1.47 (1.38, 1.57)
East Asian 15 1.48 (1.39, 1.57) 1.48 (1.39, 1.57) 1.45 (1.34, 1.57)
South Asian 16 1.69 (1.58, 1.82) 1.69 (1.58, 1.81) 1.70 (1.57, 1.83)
South-East Asian 5 1.56 (1.31, 1.87) 1.56 (1.31, 1.88) 1.46 (1.22, 1.75)
Hispanic or Latino 2 2.31 (2.12, 2.52) 2.31 (2.12, 2.52) 2.24 (2.03, 2.48)
Other/mixed 8 1.88 (1.44, 2.47) 1.90 (1.45, 2.52) 1.42 (0.85, 2.32)
Year of survey
1960–1979 7 0.45 (0.24, 0.89)
1980–1989 15 0.75 (0.46, 1.22)
1990–1999 28 0.81 (0.54, 1.22)
2000+ 38 1.00
Study design factors: visual field (VF)/intraocular pressure (IOP)
VF on all 37 1.00 1.00
VF on all and IOP criterion 5 0.55 (0.26, 1.18) 0.64 (0.35, 1.14)
IOP criterion and VF on subset 35 0.58 (0.40, 0.86) 0.78 (0.56, 0.99)
Other 11 0.90 (0.52, 1.53) 1.23 (0.77, 1.76)
Study design factors
(In surveys conducted since 2000)
Follows ISGEO and VF on all 10 1.00 1.00
Follows ISGEO and VF on subset 14 0.70 (0.37, 1.34) 0.69 (0.44, 1.10)
Does not follow ISGEO 14 1.03 (0.53, 1.91) 0.79 (0.48, 1.33)
Sex‡
Female 54 1.00 1.00
Male 54 1.33 (1.24, 1.42) 1.30 (1.22, 1.41)
Study design factors: VF/IOP.
VF on all—Identification of POAG included VF assessment on all participants and IOP was not used as a defining criterion of POAG.
VF on all and IOP criterion—Identification of POAG included VF assessment on all participants and IOP was used as a defining criterion of POAG.
IOP criterion and VF on subset—Identification of POAG did not include VF assessment on all participants and IOP was used as a defining criterion of POAG. In this group, 30/32 studies
performed VF on a subset of participants only, the remaining 2 studies21 22 did not undertake VF testing.
Other—Identification of POAG did not include VF assessment on all participants nor did POAG case definition rely on IOP criteria. In this group nine studies performed VF on a subset
of participants only; one study23 did not perform VF testing at all.
Study design factors: ISGEO.
Follow ISGEO and VF on all—Study design follows the ISGEO criteria and VF assessment was performed on all participants.
Follow ISGEO and VF on subset—Study design follows the ISGEO criteria and VF assessment was performed on a subset of participants (high-risk or proportion/consecutive).
Does not follow ISGEO—A more conventional method of determining glaucoma using a combination of optic disc features and VF defects.
*ORs are not mutually adjusted but take into account the clustering of prevalence estimates within study populations.
†ORs are mutually adjusted for all factors listed in this column, and allowing for the clustering of prevalence estimates within study populations.
‡Analysis performed on a subset of data that report prevalence by sex.
CrI, credible intervals; ISGEO, International Society for Geographical and Epidemiological Ophthalmology.
Figure 1 Proportion of studies over
time performing visual ﬁelds on all
participants or intraocular pressure to
diagnose primary open angle
glaucoma (POAG).
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age there was no evidence of habitation type on POAG preva-
lence and the OR was remarkably close to 1.0 (data not
presented).
Estimates of the global POAG prevalence by region were
attained by applying modelled age and ethnic-speciﬁc prevalence
estimates to UN deﬁned population data in 5-yearly intervals
from age 40 years onwards for calendar years 2015, 2020 and
2025 (table 4). The number of cases and population prevalence
of POAG are shown. Global estimates suggest a burden of 57.5
million (95% CI 46.4 to 73.1 million) POAG cases in 2015,
rising to 65.5 million (95% CrI 52.8, 83.2 million) in 2020.
While the prevalence of POAG is highest in Africa (4.5%),
nearly half of POAG cases (49%) are in Asia due to its consider-
ably larger population size. Although the age-speciﬁc prevalence
is stable over time, the overall prevalence of POAG is predicted
to increase by 0.1–0.2% from 2015 to 2020 because of popula-
tion ageing. The global share of POAG cases will increase in
Latin America, Asia and Africa but decrease in Europe and
North America, due to more rapid expansion of the ageing
population in these countries of non-European ancestry. Maps
showing global estimates of the number of POAG cases over
time (for 2015, 2020 and 2025) are provided as online supple-
mentary ﬁgures S2–S4. Online supplementary ﬁgures S2–S4
show changes in prevalence over time.
DISCUSSION
This systematic review and meta-analysis represents the most
up-to-date estimates of POAG prevalence and is based on the
most comprehensive data available. Compared with similar ana-
lyses, it includes twice as many studies, participants, and POAG
cases than studies published nearly a decade ago (81 vs 34
studies2 and 46 studies,5 216 214 vs 103 567 participants,5 and
5266 vs 2509 cases5 at best) and a half more cases and partici-
pants to the most recent meta-analysis (with 3370 cases,
Table 3 Estimated prevalence of primary open angle glaucoma (POAG) by age and ethnicity in men and women combined
Prevalence of POAG by age and ethnicity (%)
Age (years) White Black East Asian South Asian South-East Asian Hispanic or Latino Other/Mixed
35 0.3 (0.2, 0.4) 1.7 (1.2, 2.4) 0.7 (0.4, 1.0) 0.6 (0.4, 0.9) 0.7 (0.3, 1.5)* 0.3 (0.1, 0.8)* 0.5 (0.2, 1.0)
40 0.4 (0.2, 0.5) 2.1 (1.5, 3.0) 0.8 (0.5, 1.2) 0.8 (0.5, 1.1) 0.9 (0.4, 1.8)* 0.5 (0.2, 1.2)* 0.6 (0.3, 1.3)
45 0.5 (0.4, 0.7) 2.6 (1.9, 3.8) 1.0 (0.7, 1.5) 1.0 (0.7, 1.4) 1.1 (0.6, 2.2) 0.8 (0.3, 1.7) 0.9 (0.5, 1.6)
50 0.7 (0.5, 1.0) 3.3 (2.4, 4.7) 1.2 (0.8, 1.8) 1.3 (0.9, 1.8) 1.4 (0.8, 2.6) 1.2 (0.5, 2.6) 1.2 (0.7, 2.1)
55 1.0 (0.7, 1.4) 4.1 (3.0, 5.8) 1.5 (1.0, 2.1) 1.7 (1.2, 2.3) 1.7 (1.0, 3.1) 1.8 (0.8, 3.8) 1.7 (1.0, 2.8)
60 1.4 (1.0, 1.9) 5.2 (3.7, 7.2) 1.8 (1.2, 2.6) 2.1 (1.5, 3.0) 2.2 (1.2, 3.9) 2.7 (1.2, 5.7) 2.3 (1.4, 3.8)
65 2.0 (1.5, 2.7) 6.4 (4.7, 9.0) 2.2 (1.5, 3.1) 2.8 (2.0, 3.9) 2.7 (1.5, 4.8) 4.0 (1.8, 8.4) 3.2 (1.8, 5.3)
70 2.7 (2.1, 3.7) 8.0 (5.8, 11.1) 2.6 (1.8, 3.8) 3.6 (2.5, 5.0) 3.3 (1.9, 6.0) 5.9 (2.7, 12.2) 4.3 (2.4, 7.7)
75 3.8 (2.9, 5.1) 9.9 (7.2, 13.6) 3.2 (2.1, 4.6) 4.6 (3.2, 6.5) 4.2 (2.3, 7.5) 8.7 (4.0, 17.4) 5.8 (3.0, 11.1)
80 5.3 (4.0, 7.1) 12.2 (8.9, 16.6) 3.8 (2.6, 5.6) 5.9 (4.1, 8.4) 5.1 (2.8, 9.5)* 12.7 (6.0, 24.4) 7.9 (3.7, 16.0)
85 7.3 (5.5, 9.8) 14.9 (10.9, 20.2) 4.6 (3.1, 6.8) 7.6 (5.2, 10.8) 6.4 (3.3, 12.1)* 18.2 (8.7, 33.1) 10.5 (4.5, 22.7)*
90 10.0 (7.4, 13.5) 18.1 (13.4, 24.3) 5.5 (3.7, 8.2)* 9.6 (6.6, 13.8)* 7.8 (3.9, 15.3)* 25.2 (12.7, 43.1) 14.0 (5.4, 31.3)*
95 13.6 (10.1, 18.1) 21.8 (16.2, 29.0) 6.6 (4.4, 9.9)* 12.1 (8.2, 17.5)* 9.6 (4.5, 19.3)* 33.9 (18.0, 53.7) 18.3 (6.6, 41.6)*
Estimates correspond to prevalence (%) and 95% credible intervals,and are standardised to surveys that performed visual field but not intraocular pressure assessment on all
participants.
*Estimates obtained by extrapolation from the fitted model.
Figure 2 Estimated prevalence (%) of primary open angle glaucoma with age for men and women combined by ethnicity; (A) shows prevalence
on the y axis on the normal scale, (B) on the log scale. Coloured lines come from regression models adjusting for age (log-linear relationship), ﬁtted
separately for White (green), Black (blue), East Asian (orange), South Asian (purple), Southeast Asian (navy), Hispanic or Latino (brown), and other
or mixed ethnicity (pink) groups. Solid lines are given across the age range of available data for each ethnic group.
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Table 4 Global primary open angle glaucoma (POAG) trends: age, gender and ethnic-specific prevalence estimates applied to United Nations (UN) defined population data for age above 40 years for
2010, 2015 and 2020
UN population
Total population
(≥40 years) POAG cases (95% credible intervals)
Population
prevalence (%)
Percentage of global
prevalence
Change from 2015 to
2020
Change from 2015 to
2025
2015 2020 2025 2015 2020 2025 2015 2020 2025 2015 2020 2025
Population
(%)
Global
(%)
Population
(%)
Global
(%)
Europe 385.84 396.76 407.88 7.81 (5.92, 10.52) 8.30 (6.30, 11.18) 8.82 (6.69, 11.88) 2.0 2.1 2.2 13.6 12.7 11.8 0.1 −0.9 0.2 −1.8
Africa 225.86 264.24 311.83 10.13 (7.34, 14.14) 11.83 (8.57, 16.51) 13.93 (10.09, 19.44) 4.5 4.5 4.5 17.6 18.1 18.7 0 0.5 0 1.1
Asia 1558.06 1725.14 1907.99 28.53 (21.64, 37.54) 32.51 (24.70, 42.73) 36.98 (28.13, 48.56) 1.8 1.9 1.9 49.6 49.7 49.6 0.1 0.1 0.1 0
Western Asia 68.86 82.72 98.57 0.95 (0.71, 1.28) 1.14 (0.86, 1.54) 1.37 (1.04, 1.86) 1.4 1.4 1.4 1.6 1.7 1.8 0 0.1 0 0.2
Central Asia 18.62 21.02 23.90 0.30 (0.20, 0.43) 0.34 (0.23, 0.49) 0.39 (0.26, 0.56) 1.6 1.6 1.6 0.5 0.5 0.5 0 0 0 0
Eastern Asia 753.46 802.14 853.84 13.06 (8.88, 18.90) 14.51 (9.88, 21.00) 16.05 (10.93, 23.24) 1.7 1.8 1.9 22.7 22.2 21.5 0.1 −0.5 0.2 −1.2
Southern Asia 511.15 584.30 665.59 9.92 (7.06, 13.91) 11.50 (8.19, 16.13) 13.33 (9.49, 18.69) 1.9 2.0 2.0 17.2 17.6 17.9 0.1 0.4 0.1 0.7
South-Eastern Asia 205.97 234.95 266.09 4.03 (2.31, 7.17) 4.72 (2.70, 8.37) 5.49 (3.14, 9.74) 2.0 2.0 2.1 7.0 7.2 7.4 0 0.2 0.1 0.4
Northern America 171.08 180.56 190.70 3.30 (2.50, 4.45) 3.67 (2.79, 4.95) 4.10 (3.11, 5.52) 1.9 2.0 2.1 5.7 5.6 5.5 0.1 −0.1 0.2 −0.2
Latin America and the
Caribbean
209.76 238.23 268.01 7.07 (3.69, 13.40) 8.34 (4.33, 15.84) 9.85 (5.09, 18.69) 3.4 3.5 3.7 12.3 12.7 13.2 0.1 0.4 0.3 0.9
Central America 51.28 59.56 67.97 1.59 (0.73, 3.18) 1.92 (0.89, 3.83) 2.32 (1.07, 4.62) 3.1 3.2 3.4 2.8 2.9 3.1 0.1 0.1 0.3 0.3
Southern America 142.57 161.53 181.53 4.65 (2.15, 9.27) 5.50 (2.54, 10.94) 6.49 (3.01, 12.89) 3.3 3.4 3.6 8.1 8.4 8.7 0.1 0.3 0.3 0.6
Caribbean 15.90 17.14 18.51 0.83 (0.60, 1.14) 0.92 (0.67, 1.28) 1.03 (0.75, 1.42) 5.2 5.4 5.6 1.4 1.4 1.4 0.2 0 0.4 0
Oceania 15.87 17.28 18.86 0.31 (0.24, 0.41) 0.36 (0.27, 0.47) 0.41 (0.31, 0.54) 2.0 2.1 2.2 0.5 0.5 0.5 0.1 0 0.2 0
Australia and New
Zealand
13.29 14.29 15.45 0.26 (0.20, 0.35) 0.29 (0.22, 0.39) 0.33 (0.25, 0.45) 1.9 2.1 2.2 0.5 0.4 0.4 0.2 −0.1 0.3 −0.1
Melanesia 2.20 2.57 2.96 0.04 (0.03, 0.07) 0.05 (0.03, 0.08) 0.06 (0.04, 0.10) 1.9 2.0 2.0 0.1 0.1 0.1 0.1 0 0.1 0
Micronesia 0.17 0.19 0.20 0.004 (0.002, 0.006) 0.004 (0.003, 0.007) 0.005 (0.003, 0.009) 2.1 2.3 2.6 0.0 0.0 0.0 0.2 0 0.5 0
Polynesia 0.22 0.24 0.26 0.005 (0.003, 0.008) 0.006 (0.003, 0.010) 0.007 (0.004, 0.011) 2.3 2.4 2.6 0.0 0.0 0.0 0.1 0 0.3 0
Global 2566.47 2822.22 3105.27 57.54 (46.44, 73.07) 65.46 (52.84, 83.17) 74.62 (60.20, 94.85) 2.2 2.3 2.4 100.0 100.0 100.0 0.1 0 0.2 0
Total population and numbers of POAG cases are reported in millions.
In Europe and North America the predominant ethnicity was assumed to be White.
In Africa the predominant ethnicity was assumed to be Black.
Asia includes Western Asia (White), Central Asia (East Asian), Eastern Asia (East Asian), Southern Asia (South Asian) and South-Eastern Asia (South-East Asian).
Latin America and the Caribbean include the Caribbean (Black), Central America (Hispanic) and South America (Hispanic).
Oceania includes Australia and New Zealand (White), Melanesia (Other/Mixed), Micronesia (Other/Mixed) and Polynesia (Other/Mixed).
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140 496 participants).3 It also encompasses a greater ethnic
diversity of study populations. Due to a recent surge in Asian
population studies (23 studies reporting on 24 distinct Asian
populations since 2005), the data allow the subdivision of
results by South, East and South-Eastern Asia, and more accur-
ate prevalence estimates in this region due to the larger
numbers. This is particularly important as the worldwide POAG
case burden is greatest in Asia.
The review afﬁrms that Black populations have the highest
POAG prevalence from early middle life.4 5 This suggests that
exposure to disease is longer in Black populations, and may
explain the observation that glaucoma is more severe in Black
populations compared with White populations in an age-
matched comparisons of elderly patients.11 Age-speciﬁc increase
in POAG prevalence is highest among White populations and
Hispanic populations (Hispanics appear to overtake POAG
prevalence in Black populations in later life), followed by
Asians, and is lowest in Black populations. Reasons for these
apparent ethnic differences are unclear, and may relate to differ-
ences in anatomy, pigmentation and/or genetic susceptibility.12
They may also relate to ethnic differences in susceptibility to
other non-communicable diseases and their precursors.13–15 For
example, Black populations and Asians are at greater risk com-
pared with White populations of cardiometabolic disease (eg,
stroke, diabetes, coronary heart disease and their associated pre-
cursors), and these are putative risk factors for POAG.16 17 It is
noteworthy that as with POAG, the magnitude of these ethnic
differences are also highly dependent on age.13
Accurate modelling of POAG by age and by ethnic group is
important when obtaining global estimates, as any error is mag-
niﬁed when applied to global population numbers. This is par-
ticularly relevant at older ages where log-linear increases in
POAG compete with increasing mortality. Equally, it is import-
ant to standardise for age when comparing POAG prevalence
between populations, to ensure that any apparent population
differences are not confounded by age. While numbers with
POAG are predicted to increase due to population ageing, appli-
cation of the same POAG prevalence rates to 2015, 2020 and
2025 demographic data assume that the underlying age-speciﬁc
prevalence remains stable, and that any potential changes in
diagnostic technology and deﬁnitions will not alter the under-
lying rate of detection. While this assumption can be assumed
for the next decade (table 4 and online supplementary ﬁgures
S2–S4), we believe that further reviews are needed to extrapo-
late ﬁndings beyond 2025.
Our results show that POAG prevalence decreases with older
studies, and that year of survey is closely linked to changing
trends in study designs and diagnostic deﬁnitions. Historic
studies (1960–1979) often include raised IOP as a diagnostic cri-
terion (ﬁgure 1), and they report signiﬁcantly lower POAG
prevalence than studies after year 2000, which may be due to
missed cases of low tension glaucoma. The trend for routine VF
testing on all participants also changes with time (ﬁgure 1).
While VF results form part of the POAG case deﬁnitions in
every study included, only those conducted in 1990–2004
tended to perform VF test on all subjects (59%, ie, 27 out of 46
studies). After 2005, that drops to only 35%. The lack of com-
plete VF data is likely to cause underdiagnosis, as most POAG
case deﬁnitions require the simultaneous presence of structural
and functional changes to optic disc and VF. The move away
from routine VF testing on all participants could be linked to
the adoption of ISGEO guidelines, published in 2002.6 These
guidelines aim to improve and homogenise the diagnosis of
POAG by deﬁning a ‘normal’ optic disc using the study
populations’ own cup-to-disc ratio and applying statistical
cut-offs at 97.5th and 99.5th centiles for glaucomatous VF
changes. They allow for three diagnostic categories depending
on the level of evidence available. Crucially, those without VF
testing can be diagnosed with POAG under the ISGEO scheme,
albeit under a category of lower level of evidence and certainty.
This might have encouraged investigators to limit time-
consuming and costly VF testing to high-risk patients only.
However, incomplete VF data will affect the accuracy of ISGEO
diagnosis, as the criteria assume that all subjects had attempted
to perform VF. Those who could not satisfactorily perform VF
due to poor visual function will be diagnosed on more stringent
optic disc changes (CDR>99.5th centile rather than 97.5th
centile), but any patients with glaucoma with normal ﬁelds who
did not undergo VF testing by design will also be diagnosed on
this more stringent criteria. Moreover, the deﬁnition of the
‘normal population’ in ISGEO is open to interpretation, and
could refer to those without glaucomatous ﬁeld changes, to
‘hypernormals’ with repeated normal VF tests. As such, the
availability of VF data could bias the deﬁnitions of normal.
These limitations need to be considered carefully in future
population surveys. Our ﬁndings corroborate with our expecta-
tions, that studies which performed VF on all subjects and did
not rely on an IOP criterion, report a higher odds of POAG.
Among ISGEO studies, the completeness of VF testing is asso-
ciated with higher odds of POAG.
Although earlier systematic reviews have suggested no gender
difference after age adjustment,4 other reviews suggest that
higher prevalence in women2 18 is commensurate with clinical
representation of the disease. Our ﬁnding afﬁrms our earlier
work, and ﬁndings from a recent review,3 in showing higher
age-adjusted prevalence in men.5 Our ﬁndings are now based on
far greater numbers with 3497 POAG cases out of 146 882 par-
ticipants with gender-speciﬁc data, compared with 1355 and
61 267 in our earlier review,5 and with comparable numbers to
those used in a more recent review.3 Hence, we can be increas-
ingly conﬁdent that age-adjusted prevalence is higher in men
compared with women, and that this ﬁnding remains consistent
across all ethnic groups. As we indicated in our earlier work this
gender difference remains even when meta-analytical data sug-
gesting higher prevalence in women are included,5 and it would
take an extraordinarily large study with opposite results to alter
the overall ﬁndings. Biological reasons for this gender difference
may reﬂect anatomical difference in retinal nerve ﬁbre thick-
ness,19 or potentially protective hormonal effects among
women.20 Higher POAG prevalence in men is also akin to well
known gender differences in other non-communicable diseases,
such as cardiovascular disease, which is explained by greater
lifestyle and biological risk factors among men; risk factors that
have also been shown to be positively associated with
glaucoma.16
In contrast to a previous recent review,3 our analyses do not
support an association between POAG prevalence and habita-
tion type. However, we allowed for the association with age to
vary by ethnicity and it is likely that the effect of habitation type
observed in the previous review was due to residual
confounding.
This review has a number of strengths and limitations. The
larger number of studies reﬂects the inclusive approach adopted,
which allows all studies with potentially relevant data to con-
tribute to the meta-analysis. In contrast to the most recent
review,3 our estimates were standardised to studies with optimal
methods, while allowing studies with suboptimal methods to
contribute to pooled estimates compensating for study
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differences. Adopting a more exclusive approach, that is, omit-
ting studies with imperfect study methods, would result in loss
of power and would not allow the effect of study differences to
be quantiﬁed. Consequent to our large data set, our estimates
were associated with greater accuracy. For example, previous
estimates of the global number of POAG cases suggests 44.1
million cases in 2013, but the 95% CIs range from 31.3 million
to 60.9 million, representing a twofold difference.3 Our esti-
mate of 57.5 million global POAG cases in 2015, is comparable
to this earlier estimate (ie, the point estimate is contained within
the CI),3 but has a narrower 95% CrI of 46.4 million to 73.1
million (ie, a 1.6-fold difference). The same occurs for 2020,
where we produce a similar but more precise estimate than
earlier estimates.3 The improved accuracy is important to the
appropriate planning of health service provision, especially as
earlier estimates could result in a potential doubling or halving
of economic costs.3
Limitations of this study include the omission of study
response rates in the analysis as reliable data were difﬁcult to
obtain, and that formal participation rates (ie, the number with
data/number invited) were not routinely reported. However, our
earlier work suggests that non-response has a minimal effect on
POAG estimates,5 and agrees with other work3 that could not
elicit a reliable estimate for response rates. Second, the use of
ethnicity-based estimates to generate global and regional POAG
prevalence means that multiethnic populations will not be
adequately represented by our estimates based on the single pre-
dominant ethnic group of the region. In addition, it assumes
that populations of the same ethnicity settled in different geo-
graphical locations share similar POAG risks, which conﬂicts
with the understanding that POAG susceptibility is a product of
environmental factors and genetics. Despite these caveats we
believe our estimates provide greater certainty than comparable
studies.3
In summary, this meta-analysis provides the most comprehen-
sive and current evidence on POAG prevalence. The results cor-
roborate with the previous predicted trend of more rapid
increases in POAG cases in developing countries on
non-European ancestry, due to more aged population expansion,
and reiterate the ﬁnding of greater prevalence among men than
women, and among Black populations and older Hispanic
populations. However, the changing study design methods and
glaucoma deﬁnitions through time highlight the difﬁculty
researchers had and still experience in attempting to adequately
deﬁne POAG. The study provides clear recommendations for
the use and interpretation of study methods, particularly ISGEO
guidelines,6 in the future.
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